Literature DB >> 3902958

What is cholestasis in 1985?

S Erlinger.   

Abstract

Bile secretion involves a number of specific transport systems in the hepatocytes. These are located at the baso-lateral membrane (bile acid/sodium co-transport, sodium/proton exchange), intracellularly or at the canalicular membrane (bile acid secretory carrier, bicarbonate transport system). In addition, the paracellular (tight junction) pathway allows passage of inorganic ions and waters. Cholestasis may result from an alteration of these transport systems (hepatocellular cholestasis), from obstruction of intrahepatic bile ducts or obstruction of extrahepatic bile ducts. The main proposed mechanisms of hepatocellular cholestasis are reviewed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3902958     DOI: 10.1016/s0168-8278(85)80012-x

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

2.  Sweroside ameliorates α-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responses.

Authors:  Qiao-Ling Yang; Fan Yang; Jun-Ting Gong; Xiao-Wen Tang; Guang-Yun Wang; Zheng-Tao Wang; Li Yang
Journal:  Acta Pharmacol Sin       Date:  2016-08-08       Impact factor: 6.150

Review 3.  Cellular mechanisms of intrahepatic cholestasis.

Authors:  P J Meier-Abt
Journal:  Drugs       Date:  1990       Impact factor: 9.546

4.  Drug-Induced Liver Injury. Cholestatic Injury, Acute and Chronic.

Authors:  Claude Degott
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

Review 5.  Drug-induced cholestasis.

Authors:  H J Zimmerman; J H Lewis
Journal:  Med Toxicol       Date:  1987 Mar-Apr

6.  A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis.

Authors:  Peter Fickert; Ulrike Stöger; Andrea Fuchsbichler; Tarek Moustafa; Hanns-Ulrich Marschall; Andreas H Weiglein; Oleksiy Tsybrovskyy; Hartmut Jaeschke; Kurt Zatloukal; Helmut Denk; Michael Trauner
Journal:  Am J Pathol       Date:  2007-06-28       Impact factor: 4.307

Review 7.  Nuclear receptors as drug targets in cholestatic liver diseases.

Authors:  Emina Halilbasic; Anna Baghdasaryan; Michael Trauner
Journal:  Clin Liver Dis       Date:  2013-05       Impact factor: 6.126

Review 8.  Fibrotic Events in the Progression of Cholestatic Liver Disease.

Authors:  Hanghang Wu; Chaobo Chen; Siham Ziani; Leonard J Nelson; Matías A Ávila; Yulia A Nevzorova; Francisco Javier Cubero
Journal:  Cells       Date:  2021-05-05       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.